Jeffrey A. Bluestone Joins Gilead Sciences’ Board of Directors
December 08 2020 - 4:05PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that
Jeffrey A. Bluestone, PhD, has been appointed to the company’s
Board of Directors.
Dr. Bluestone is the President and Chief Executive Officer of
Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen
Distinguished Professor of Metabolism and Endocrinology at the
University of California San Francisco. He is an international
leader in the field of immunotherapy and has published more than
500 papers over nearly four decades focused on understanding the
basic processes that control T-cell activation and immune tolerance
in autoimmunity, organ transplantation and cancer. His research has
led to the development of multiple immunotherapies, including the
first medicine approved by the U.S. Food and Drug Administration
(FDA) targeting T-cell co-stimulation to treat autoimmunity and the
first FDA-approved checkpoint inhibitor for the treatment of
metastatic melanoma. Dr. Bluestone was the founding director of the
Immune Tolerance Network, the largest National Institutes of
Health-funded multicenter clinical immunology research program,
testing novel immunotherapies in transplantation, autoimmunity and
asthma/allergy. He recently led the Parker Institute for Cancer
Immunotherapy as President and Chief Executive Officer. He served
as a member of the Blue Ribbon Panel, appointed by then Vice
President Joe Biden, to guide the National Cancer Moonshot
Initiative. Dr. Bluestone is a member of the National Academy of
Medicine and American Academy of Arts and Sciences, was a recipient
of the prestigious Guggenheim Fellowship, and previously served as
the Ludwig Professor and Director of the Ben May Institute at the
University of Chicago.
“We are very pleased to welcome Jeff Bluestone to our Board of
Directors,” said Daniel O’Day, Chairman and Chief Executive Officer
of Gilead Sciences. “Jeff is an exceptional scientist and
researcher who has had a distinguished career in the field of
immunotherapy. His scientific acumen will be a valuable addition to
the Gilead Board, as we continue to deliver transformational
medicines to patients.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201208006055/en/
Douglas Maffei, PhD, Investors (650) 522-2739
Marni Kottle, Media (650) 522-5388
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024